A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells
Analyzing memory B cell repertoires of the healthy elderly enabled Michalon et al. to develop a recombinant human antibody selective for transthyretin amyloid. This antibody removes cardiac amyloid through recruitment of phagocytic immune cells.
Guardado en:
Autores principales: | Aubin Michalon, Andreas Hagenbuch, Christian Huy, Evita Varela, Benoit Combaluzier, Thibaud Damy, Ole B. Suhr, Maria J. Saraiva, Christoph Hock, Roger M. Nitsch, Jan Grimm |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0bd15e092d1f47498ea907338e89a448 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
por: J Gustav Smith, et al.
Publicado: (2021) -
Stochastic master equation for early protein aggregation in the transthyretin amyloid disease
por: Ruo-Nan Liu, et al.
Publicado: (2020) -
Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin
por: Genki Suenaga, et al.
Publicado: (2017) -
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment
por: Silvia Oghina, et al.
Publicado: (2021) -
A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy
por: Ahsan Huda, et al.
Publicado: (2021)